top of page


an unmet need

Osteoarthritis (OA), a degenerative joint disease characterized by progressive articular cartilage loss and intermittent inflammation, is among the most frequently diagnosed diseases and a leading cause of disability in the western world. However, perhaps surprisingly, despite these trends, there are no drugs available (yet) that can halt or reverse the process, with palliative care or surgery frequently being the only options available. The development of effective drugs has been hampered by the lack of experimental models that can adequately mimic the disease.

The miracle of cartilage cells in 3D


Pregenerate’ s Optimate OA™ is a game-changing technology that accurately and reliably mimics the joint environment by combining novel microfluidic engineering (capillary- and shear force driven) principles, 3D cell cultivation methods and geometric design constraints of the microchambers to drive native-like cellular behaviour. Read more about the science behind.

Breakthrough innovation, OptimateOA™ provides human life-like conditions, for unlimited experiments "in human", evaluation of the so needed OA biomarkers to leverage disease understanding.

As 1st 3D human model, OptimateOA™ can help scientists better understand the underlying mechanisms of osteoarthritis, to accelerate R&D, new drug discovery, development and validation to market. It will ultimately allow precision medicine in OA.

Changing the Game

Pregenerate’s Cartilage-on-a-chip® based test allows to evaluate individual response profile to osteoarthritis treatments, analysing expression of genes representative of inflammation, regeneration and degeneration. Thus evaluating how the patient' cells would react to treatment prior to administration, empowering physicians and patients in making appropriate, informed treatment selection.

Misty Slope

How to unlock Osteoarthritis Management?

OA is a complex and unhomogeneous serious disease.

Accelerating R&D, in a time and cost-saving way, our technology holds promise to stimulate the development of new OA drugs, thus make an unprecedented impact on clinical practice and OA patients' lives.

To understand the need for biomarkers' evaluation in OA, at R&D, and clinical management levels, highlighted by experts and by the FDA, review the brilliant recent publication in Nature Reviews Rheumatology, by Ali Mobasheri and Richard Loeser: "Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development".

To learn how we can help unlock OA drug development, contact us.

Artifical Intelligence Data representation


for microscopy imaging and gene expression profiling

Recent studies (Hall A. C. (2019)) have identified early changes to human chondrocyte morphology and volume occurring before marked cartilage degeneration and loss. Our understanding of early stages of tissue failure can be aided by modern data science tools including machine learning approaches that can provide stratified clinical decision support. This is fascinating and enlightening for our teams. 

If you want to know how we plan to disrupt OA by bringing AI in our development of innvative solutions, just contact us.

bottom of page